Coeptis Therapeutics, Inc.
COEP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11 | $403 | $438 | $204 |
| - Cash | $1 | $1 | $4 | $2 |
| + Debt | $1 | $1 | $2 | $4 |
| Enterprise Value | $11 | $403 | $436 | $206 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$1 | -$1 | -$1 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$9 | -$20 | -$36 | -$13 |
| % Margin | – | – | – | -17,086.3% |
| Net Income | -$11 | -$21 | -$38 | -$13 |
| % Margin | – | – | – | -17,932.4% |
| EPS Diluted | -5.65 | -0.83 | -2.87 | -13.16 |
| % Growth | -580.7% | 71.1% | 78.2% | – |
| Operating Cash Flow | -$7 | -$7 | -$4 | -$4 |
| Capital Expenditures | $0 | $0 | $0 | -$2 |
| Free Cash Flow | -$7 | -$7 | -$4 | -$6 |